Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Eton Pharmaceuticals (ETON) Gross Margin (2019 - 2025)

Eton Pharmaceuticals' Gross Margin history spans 7 years, with the latest figure at 61.56% for Q4 2025.

  • On a quarterly basis, Gross Margin rose 595.0% to 61.56% in Q4 2025 year-over-year; TTM through Dec 2025 was 66.31%, a 630.0% increase, with the full-year FY2025 number at 53.46%, down 655.0% from a year prior.
  • Gross Margin hit 61.56% in Q4 2025 for Eton Pharmaceuticals, up from 34.97% in the prior quarter.
  • Over the last five years, Gross Margin for ETON hit a ceiling of 552.13% in Q1 2025 and a floor of 12.18% in Q4 2023.
  • Historically, Gross Margin has averaged 87.65% across 5 years, with a median of 62.77% in 2024.
  • Biggest five-year swings in Gross Margin: crashed -720611bps in 2021 and later skyrocketed 48927bps in 2025.
  • Tracing ETON's Gross Margin over 5 years: stood at 93.89% in 2021, then dropped by -20bps to 74.84% in 2022, then tumbled by -84bps to 12.18% in 2023, then soared by 356bps to 55.6% in 2024, then grew by 11bps to 61.56% in 2025.
  • Business Quant data shows Gross Margin for ETON at 61.56% in Q4 2025, 34.97% in Q3 2025, and 63.0% in Q2 2025.